^
Association details:
| Biomarker: | EGFR mutation |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | SIBP-04 (bevacizumab biosimilar) (VEGF-A inhibitor, Angiogenesis inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Outcome benefits of bevacizumab biosimilar (SIBP04) combined with carboplatin and paclitaxel in advanced non-squamous non-small-cell lung cancer patients with EGFR mutation: subgroup analysis of a prospective, randomized phase III clinical trial
Published date:
07/15/2023
Excerpt:
All patients received 4 to 6 cycles of paclitaxel and carboplatin plus SIBP04 or bevacizumab 15 mg/kg intravenously followed by SIBP04 15 mg/kg maintenance until intolerable toxicity, disease progression or death. Patients with EGFR mutation and wild-type were assessed for progression-free survival (PFS) and overall survival (OS)....Bevacizumab combined with chemotherapy significantly prolonged the PFS and OS of advanced nsqNSCLC patients with EGFR mutation.
Secondary therapy:
carboplatin + paclitaxel
DOI:
10.1007/s00432-023-05103-4
Trial ID:
